Dyspnea in interstitial lung disease

Current Opinion in Supportive and Palliative Care

Volumn 2, Issue 2, 2008, Pages 100-104

  Collard, Harold R ^a,b   Pantilat, Steven Z ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dyspnea; Epidemiology; Etiology; Interstitial lung disease; Management; Measurement; Pulmonary fibrosis

Indexed keywords

DYSPNEA; FEMALE; HOSPITALIZATION; HUMAN; INTERSTITIAL LUNG DISEASE; MALE; MIDDLE AGED; OXYGEN THERAPY; PROGNOSIS; REVIEW;

DYSPNEA; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; OXYGEN INHALATION THERAPY; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 55949109138     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e3282ff6336     Document Type: Article

References (23)

1. Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 157:199-203.
2. Collard HR, King TE Jr, Bartelson BB, et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168:538-542.
3. Flaherty KR, Toews GB, Lynch JP III, et al. Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. Am J Med 2001; 110:278-282.
4. Watters LC, King TE, Schwarz MI, et al. A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis 1986; 133:97-103.
5. Beach D, Schwartzstein R. The genesis of breathlessness: what do we understand? In: Booth S, Dudgeon D, editors. Dyspnoea in advanced disease: a guide to clinical management. Oxford: Oxford University Press; 2006.pp. 1-18.
6. O'Donnell D, Voduc N. Mechanisms of dyspnea in restrictive lung disease. In: Mahler DA, O'Donnell D, editors. Dyspnea: mechanisms, measurement, and management, 2nd ed. Boca Raton: Taylor and Francis Group; 2005. pp. 87-113.
7. Mahler DA, Baird JC. Dyspnea in the elderly. In: Mahler DA, O'Donnell D, editors. Dyspnea: mechanisms, measurement, and management. Boca Raton: Taylor and Francis Group; 2005 pp. 19-28.
8. Martinez J, Martinez T, Galhardo F, Pereira C. Dyspnea scales as a measure of health-related quality of life in patients with idiopathic pulmonary fibrosis. Med Sci Monit 2002; 8:CR405-CR410.
9. Mahler DA, Ward J, Fierro-Carrion G, et al. Development of self-administered versions of modified baseline and transition dyspnea indexes in COPD. COPD 2004; 1:165-172.
10. Tzanakis N, Samiou M, Lambiri I, etal. Evaluation of health-related quality-of- life and dyspnea scales in patients with idiopathic pulmonary fibrosis. Correlation with pulmonary function tests. Eur J Intern Med 2005;16:105-112.
11. Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003; 168:531 -537.
12. King TE Jr, Behr J, Brown KK, etal. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177:75-81.
13. Witek TJ Jr, Mahler DA. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J 2003;21:267-272.
14. Naji NA, Connor MC, Donnelly SC, McDonnell TJ. Effectiveness of pulmonary rehabilitation in restrictive lung disease. J Cardiopulm Rehabil 2006; 26:237-243.
15. Jastrzebski D, Gumola A, Gawlik R, Kozielski J. Dyspnea and quality of life in patients with pulmonary fibrosis after six weeks of respiratory rehabilitation. J Physiol Pharmacol 2006; 57 (Suppl 4):139-148.
16. Jennings AL, Davies AN, Higgins JP, et al. A systematic review of the use of opioids in the management of dyspnoea. Thorax 2002; 57:939-944.
17. Kupferberg DH, Kaplan RM, Slymen DJ, Ries AL. Minimal clinically important difference for the UCSD shortness of breath questionnaire. J Cardiopulm Rehabil 2005; 25:370-377.
18. Guyatt GH, Berman LB, Townsend M, et al. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987; 42:773-778.
19. Mahler DA, Harver A, Lentine T, et al. Descriptors of breathlessness in cardiorespiratory diseases. Am J Respir Crit Care Med 1996; 154:1357-1363.
20. Borg GA. Psychophysical bases ofperceived exertion. Med Sci Sports Exerc 1982; 14:377-381.
21. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353:2229-2242.
22. Raghu G, Brown KK, Bradford WZ, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004; 350:125-133.
23. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005; 171:1040-1047.